Breaking News
Japan Launches Studies For Pfizer's COVID-19 Vaccine
October 21, 2020 • 9:09 am CDT
Reuters reported Pfizer and BioNTech SE announced on October 20, 2020, launching combined Phase I and Phase II clinical trials in Japan of their mRNA vaccine candidate BNT162, which is targeted against the SARS-CoV-2 coronavirus.
Pfizer's CEO Albert Bourla recently stated 'Pfizer expects to have the safety data from BNT162 in the third week of November 2020.'